0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > EphB4

EphB4

Brief Information

Name:Ephrin type-B receptor 4
Target Synonym:Ephrin type-B receptor 4,MYK1,EPHB4,HTK,EPH Receptor B4,Tyrosine-Protein Kinase TYRO11,TYRO11,Tyrosine-Protein Kinase Receptor HTK,Soluble EPHB4 Variant 2,Soluble EPHB4 Variant 3,Ephrin Receptor EphB4,EC 2.7.10.1,HFASD,LMPHM7,CMAVM2,EC 2.7.10,EC:2.7.10.1,Soluble EPHB4 Variant 1,Receptor, EphB4,Hepatoma transmembrane kinase
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
EP4-H8229 Human Biotinylated Human EphB4 Protein, His Tag, ultra sensitivity (primary amine labeling)
EP4-H8229-structure
EP4-H8229-sds
EP4-H5229 Human Human EphB4 Protein, His Tag
EP4-H5229-structure
EP4-H5229-sds
ACRO Quality

Synonym Name

EphB4,HTK,MYK1,TYRO11

Background

Ephrin type-B receptor 4(EPHB4) is also known as HTK, MYK1 and TYRO11,is a member of Eph family. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. The protein encoded by EPHB4 binds to Ephrin-B2 and plays an essential role in vascular development. EPHB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EPHB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis and tumor growth. Incontrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EPHB4 is associated with prostate cancer and highly malignant breast cancers, accordingly, EPHB4 has potential application as a therapeutic candidate.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
sEphB4-HSA Vas-01; sEphB4-HSA Phase 2 Clinical Vasgene Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Kaposi; Carcinoma, Non-Small-Cell Lung; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Philadelphia Chromosome; Bile Duct Neoplasms; Prostatic Neoplasms; Sarcoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Leukemia, Lymphoid; Solid tumours; Bone Marrow Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken